Japan Mouth Ulcer Therapeutics Market Analysis

Japan Mouth Ulcer Therapeutics Market Executive Summary

The Japan Mouth Ulcer Therapeutics Market is at around $94.5 Mn in 2023 and is projected to reach $127.7 Mn in 2030, exhibiting a CAGR of 4.4% during the forecast period 2023-2030.

Canker sores, or mouth ulcers, come in three main types: minor (small and oval), major (larger and deeper), and herpetiform (multiple small ulcers that may merge). While the exact cause is unclear, risk factors include stress, hormonal changes, nutrient deficiencies, certain diseases, and oral trauma. These ulcers typically heal on their own within 1-2 weeks but can lead to complications like infections, severe pain affecting eating, and potential scarring. Prevention focuses on stress reduction, avoiding trigger foods, using gentle oral care products, and addressing potential vitamin deficiencies. Treatment aims to relieve symptoms through topical medications, pain relief, and supportive care. Home remedies include maintaining good oral hygiene, salt water rinses, and a balanced diet. Medical attention is advised for persistent, unusual, or severe ulcers, especially if accompanied by fever or difficulty in oral functions.

The prevalence of oral aphthous ulcers in Japan was found to be 31%. The market therefore is driven by significant factors like increasing prevalence of mouth ulcers, increasing tobacco consumption, and an aging demographic, however, factors such as limited awareness and stigma, dominance of OTC medications, and high cost of prescription medications limit market growth.

The industry is primarily dominated by players such as Takeda Pharmaceuticals, Otsuku Pharmaceuticals, Eisai, Daiichi Sankyo, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Pfizer, Inc. among others.

Market Dynamics

Market Growth Drivers

Increase Prevalence of Mouth Ulcers: The prevalence rate of mouth ulcers in Japan is approximately around 31%. The high incidence of mouth ulcers creates a substantial demand for effective treatment options to alleviate pain, promote healing, and prevent recurrence. As the prevalence rates continue to rise, driven by factors such as stress, dietary habits, and certain medical conditions, the need for accessible and affordable treatments becomes increasingly critical, fueling market growth.

Increasing Tobacco Consumption: The rising consumption of tobacco products, including cigarettes and smokeless tobacco, is a significant risk factor for the development of mouth ulcers and other oral health issues. The rising consumption of tobacco among the population is contributing to the growth of the mouth ulcer treatment market.

Aging Population: The Japanese population is aging, and elderly individuals are more susceptible to oral health issues, including mouth ulcers, due to factors such as weakened immune systems, medication side effects, and underlying medical conditions.

Market Restraints

Limited Awareness and Stigma: Mouth ulcers are considered a minor inconvenience and may not be taken seriously by patients, leading to delayed treatment or self-medication. Many people may not be aware of the available treatment options or the importance of seeking professional care for persistent or recurrent ulcers.

Dominance of OTC Medications: The availability of a wide range of OTC mouth ulcer medications has made it convenient for patients to self-treat, potentially delaying diagnosis of underlying conditions. OTC products may not address the specific causes or severity of mouth ulcers, limiting their effectiveness.

High Cost of Prescription Medications: Prescription medications for mouth ulcers can be expensive, making them inaccessible to some patients, especially those without health insurance. Reimbursement policies for mouth ulcer treatments may vary, and patients may face difficulties in obtaining coverage for prescription medications.

Regulatory Landscape and Reimbursement Scenario

PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare. Our obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices. PMDA conducts scientific reviews of marketing authorization applications (MAA) for medicinal products and monitors post-marketing safety data. PMDA works with the Ministry of Health, Labour, and Welfare (MHLW) to protect the public health safety of Japan. Within PMDA, the Office of Cellular and Tissue-based Products is responsible for regulating cellular therapy products. Health Insurance Bureau develops ideas and plans on medical insurance systems including health insurance, national health insurance, seamen's insurance and medical care for the elderly to stabilize the medical insurance system for long time so that all people can access medical care without worries in a full-fledged aging society with fewer children in the future.

Competitive Landscape

Key Players

Here are some of the major key players in the Japan Mouth Ulcers Therapeutics Market:

• Takeda Pharmaceuticals
• Otsuka Pharmaceuticals
• Eisai
• Daiichi Sankyo
• Pfizer, Inc.
• Sun Pharma
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Bayer
• AstraZeneca